Prostate-specific antigen doubling time among Japanese men in an annual health screening program

International Journal of Urology

Volumn 11, Issue 10, 2004, Pages 856-861

  Terai, Akito ^a   Matsui, Yoshiyuki ^a   Ichioka, Kentaro ^a   Ohara, Hiroki ^a   Terada, Naoki ^a   Yoshimura, Koji ^a  

^a KURASHIKI CENTRAL HOSPITAL   (Japan)

Author keywords

Multiphasic screening; Prostate specific antigen; Prostate specific antigen doubling time

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER;

ADULT; AGED; HUMANS; JAPAN; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 8544225009     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2004.00904.x     Document Type: Article

References (20)

1. Noldus J, Stamey TA. Histological characteristics of radical prostatectomy specimens in men with a serum prostate specific antigen of 4 ng./ml. or less. J. Urol. 1996; 155: 441-3.
2. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6-4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997; 277: 1452-5.
3. Lodding P, Aus G, Bergdahl S et al. Characteristics of screening detected prostate cancer in men 50-66 years old with 3-4 ng/ml prostate specific antigen. J. Urol. 1998; 159: 899-903.
4. Schröder FH, van der Cruijsen-Koeter I, de Koning HJ, Vis AN, Hoedemaeker RF, Kranse R. Prostate cancer detection at low prostate specific antigen. J. Urol. 2000; 163: 806-12.
5. Babaian RJ, Johnston DA, Naccarato W, Ayala A, Bhadkamker VA, Fritsche HA Jr. The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml relation to biopsy strategy. J. Urol. 2001; 165: 757-60.
6. Krumholtz JS, Carvalhal GF, Ramos CG et al. Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features. Urology 2002; 60: 469-74.
7. Schmid HP, McNeal JE, Stamey TA. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 1993; 71: 2031-40.
8. Lee WR, Hanks GE, Corn BW, Schultheiss TE. Observations of pretreatment prostate-specific antigen doubling time in 107 patients referred for definitive radiotherapy. Int. J. Radiat. Oncol. Biol. Phys 1995; 31: 21-4.
9. Goluboff ET, Heitjan DF, deVries GM, Katz AE, Benson MC, Olsson CA. Pretreatment prostate specific antigen doubling times: use in patients before radical prostatectomy. J. Urol. 1997; 158: 1876-9.
10. Nam RK, Klotz LH, Jewett MAS, Danjoux C, Trachtenberg J. Prostate specific antigen velocity as a measure of the natural history of prostate cancer: defining a 'rapid riser' subset. Br. J. Urol. 1998; 81: 100-104.
11. Gerber GS, Gornik HL, Goldfischer ER, Chodak GW, Rukstalis DB. Evaluation of changes in prostate specific antigen in clinically localized prostate cancer managed without initial therapy. J. Urol. 1998; 159: 1243-6.
12. McLaren DB, McKenzie M, Duncan G, Pickles T. Watchful waiting or watchful progression? Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma. Cancer 1998; 82: 342-8.
13. Egawa S, Matsumoto K, Suyama K, Iwamura M, Kuwao S, Baba S. Observations of prostate specific antigen doubling time in Japanese patients with nonmetastatic prostate carcinoma. Cancer 1999; 86: 463-9.
14. Egawa S, Arai Y, Tobisu K et al. Use of pretreatment prostate-specific antigen doubling time to predict outcome after radical prostatectomy. Prostate Cancer Prostatic Dis. 2000; 3: 269-74.
15. Stephenson AJ, Aprikian AG, Souhami L et al. Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer. Urology 2002; 59: 652-6.
16. Kakehi Y, Kamoto T, Shiraishi T et al. Correlation of initial PSA level and biopsy features with PSA-doubling time in early stage prostate cancers in Japanese men. Eur. Urol. 2002; 41: 47-53.
17. Choo R, Klotz L, Danjoux C et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J. Urol. 2002; 167: 1664-9.
18. Ito K, Yamamoto T, Ohi M et al. Natural history of PSA increase with and without prostate cancer. Urology 2003; 62: 64-9.
19. Carter HB, Morrell CH, Pearson JD et al. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostatic disease. Cancer Res. 1992; 52: 3323-8.
20. Whittemore AS, Lele C, Friedman GD, Stamey T, Vogelman JH, Orentreich N. Prostate-specific antigen as predictor of prostate cancer in black men and white men. J. Natl. Cancer Inst. 1995; 87: 354-60.